Pharmacokinetics and nephrotoxicity of cisplatin modulated by combination therap...

연구 요약

Pharmacokinetics and nephrotoxicity of cisplatin modulated by combination therapy with brusatol.

Frontiers in pharmacology 학술지에 발표된 이 연구는 Guo N, Zhang Y, Yuan G 외 연구팀이 수행하였습니다.

이 연구는 'Pharmacokinetics and nephrotoxicity of cisplatin modulated by combination therapy with brusatol.'에 대한 과학적 분석을 제공합니다.

핵심 내용

ETHNOPHARMACOLOGICAL RELEVANCE: Quassinoid brusatol, isolated from the traditional Chinese medicine Brucea javanica (L.) Merr., significantly increases the intracellular concentration of cisplatin and reduces tumor size by inhibiting the Nrf2 pathway. However, the underlying mechanism remains unclear. OBJECTIVE: This study focuses on the effects of brusatol on plasma pharmacokinetics, tissue distribution, and nephrotoxicity of cisplatin. MATERIALS AND METHODS: For the pharmacokinetic study, 120 Kunming mice were randomly assigned to receive cisplatin (10 mg/kg) alone or in combination with brusatol (2 mg/kg). Blood and tissue samples were collected to evaluate the in vivo pharmacokinetic interaction. In the nephrotoxicity study, 30 Kunming mice were randomly divided into groups to receive cisplatin (10 mg/kg) alone or brusatol pretreatment (1 mg/kg or 2 mg/kg). Two control groups received brusatol (1 mg/kg) or solvent. Blood samples and kidney tissues were collected to investigate the underlying mechanisms of toxicity. RESULTS: The developed HPLC-MS method demonstrated high precision and accuracy, meeting the requirements for biological sample analysis. Brusatol reduced the plasma concentration of cisplatin, increased the apparent volume of distribution (Vd), and significantly increased cisplatin concentrations in the kidney and lung, particularly in the kidney. Combined with brusatol, serum levels of blood urea nitrogen and creatinine increased, antioxidant indices in kidney tissue decreased, and inflammatory factors increased. Pathological findings revealed increased tubular congestion. DISCUSSION AND CONCLUSION: Brusatol increases renal cisplatin concentrations by altering its pharmacokinetics, intensifying dose-dependent nephrotoxicity. Further development as a chemotherapy sensitizer requires understanding the mechanisms of this effect and optimizing the combined dose.

일반인을 위한 해석

구체적인 실천 사항은 담당 의사 또는 약사와 상담하시기 바랍니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 41737553)

📄 [전문 보기 (Markdown)](fulltext/41737553-pharmacokinetics-and-nephrotoxicity-of-cisplatin-modulated-b.md)